JAZZ is expected to report earnings to fall 2.52% to $6.18 per share on August 05
Q2'26
Est.
$6.18
Q1'26
Beat
by $1.72
Q4'25
Beat
by $0.25
Q3'25
Beat
by $2.20
Q2'25
Missed
by $0.63
The last earnings report on May 05 showed earnings per share of $6.34, beating the estimate of $4.62. With 448.29K shares outstanding, the current market capitalization sits at 14.90B.
A.I. Advisor
published General Information
General Information
a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products
A.I.dvisor indicates that over the last year, JAZZ has been loosely correlated with ZYME. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if JAZZ jumps, then ZYME could also see price increases.
Momentum Indicator for JAZZ turns positive, indicating new upward trend
JAZZ saw its Momentum Indicator move above the 0 level on June 29, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 93 similar instances where the indicator turned positive. In of the 93 cases, the stock moved higher in the following days. The odds of a move higher are at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for JAZZ just turned positive on June 30, 2026. Looking at past instances where JAZZ's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where JAZZ advanced for three days, in of 296 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The 10-day RSI Indicator for JAZZ moved out of overbought territory on July 09, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JAZZ declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
JAZZ broke above its upper Bollinger Band on July 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for JAZZ entered a downward trend on June 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. JAZZ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.288) is normal, around the industry mean (22.885). JAZZ's P/E Ratio (2156.591) is considerably higher than the industry average of (37.796). Projected Growth (PEG Ratio) (0.941) is also within normal values, averaging (2.508). JAZZ has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (3.328) is also within normal values, averaging (434.181).
Jazz Pharmaceuticals (JAZZ) stock Forecast, Price Targets and Analysts Predictions - Tickeron.com
